Adding tocilizumab to standard treatment for newly diagnosed leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding tocilizumab (a drug that calms inflammation) to the standard combination of venetoclax and azacitidine helps treat newly diagnosed acute myeloid leukemia (AML) in patients who cannot have intensive chemotherapy. It aims to reduce inflammation and improve how well the chemotherapy works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a first-time (newly diagnosed) acute myeloid leukemia (AML) diagnosis that has not yet been treated.
- You must be considered eligible for a non-intensive chemotherapy combination called azacitidine and venetoclax, and not eligible for the more intensive "3+7" regimen.
- Your performance status (a measure of how well you can do daily activities) must be reasonably good — up to an ECOG score of 3.
- Your liver test results must be within acceptable limits: liver enzymes (transaminases) less than 3 times the normal upper limit, and bilirubin less than 1.5 times the normal upper limit.
- Your kidney function (creatinine clearance) must be greater than 30 ml/min.
- You must not have an uncontrolled infection, and must not have active or treated hepatitis B, hepatitis C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs—venetoclax and azacitidine—for people with acute myeloid leukemia (AML) who can't have standard intensive chemo. The goal is to see if adding a boosting medicine (cobicistat) makes the treatment work better and is safe for you.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This Phase 2 study tests whether venetoclax combined with azacitidine can treat newly diagnosed T-ALL, a type of leukemia. It may help reduce cancer activity and improve outcomes if you meet the safety and treatment timing requirements.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
Hear when a new Leukemia Acute Myeloid - AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.